SEARCH

SEARCH BY CITATION

References

  • 1
    Drenth JP, van der Meer JW. Hereditary periodic fever. N Engl J Med 2001;345:174857.
  • 2
    Bakkaloglu A. Familial Mediterranean fever. Pediatr Nephrol 2003;18:8539.
  • 3
    Ben-Chetrit E, Levy M. Familial Mediterranean fever. Lancet 1998;351:65964.
  • 4
    Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med 1967;43:22753.
  • 5
    Cattan D, Notarnicola C, Molinari N, Touitou I. Inflammatory bowel disease in non-Ashkenazi Jews with familial Mediterranean fever. Lancet 2000;355:3789.
  • 6
    Gershoni-Baruch R, Brik R, Shinawi M, Livneh A. The differential contribution of MEFV mutant alleles to the clinical profile of familial Mediterranean fever. Eur J Hum Genet 2002;10:1459.
  • 7
    Rogers DB, Shohat M, Petersen GM, Bickal J, Congleton J, Schwabe AD et al. Familial Mediterranean fever in Armenians: autosomal recessive inheritance with high gene frequency. Am J Med Genet 1989;34:16872.
  • 8
    Torosyan L, Aksentijevich I, Sarkisian T. A population based survey reveals an extremely high FMF carrier frequency in Armenia suggesting heterozygote advantage. Am J Hum Genet 2000;67:A2275.
  • 9
    Daniels M, Shohat T, Brenner-Ullman A, Shohat M. Familial Mediterranean fever: high gene frequency among the non-Ashkenazic and Ashkenazic Jewish populations in Israel. Am J Med Genet 1995;55:3114.
  • 10
    Yilmaz E, Ozen S, Balci B, Duzova A, Topaloglu R, Besbas N et al. Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet 2001;9:5535.
  • 11
    La Regina M, Nucera G, Diaco M, Procopio A, Gasbarrini G, Notarnicola C et al. Familial Mediterranean fever is no longer a rare disease in Italy. Eur J Hum Genet 2003;11:506.
  • 12
    Portincasa P, Ruggiero V, Bonfrate L, Castorani L, Scaccianoce G, Piglionica D et al. Impaired gastrointestinal motorfunction in patients with Familial Mediterranean fever. Eur J Clin Invest 2012;42:87.
  • 13
    Portincasa P, Stella A, Bagnulo R, Ruggiero V, Bonfrate L, Castorani L et al. Genotypical/phenotypical characterization of a novel cluster of patients with familial Mediterranean fever (FMF) in Apulia and Lucania in Southern Italy. Eur J Clin Invest 2013;43:72.
  • 14
    Portincasa P, Ruggiero V, Bonfrate L, Scaccianoce G, Piglionica D, Wang DQ et al. A novel cluster of patients with Familial Mediterranean Fever (FMF) displayed abnormal gastrointestinal motorfunction. Gastroenterology 2012;142:S167.
  • 15
    Watkins JB, Graeme-Cook FM, Samuels J. Case 25-1999. N Engl J Med 1999;341:5939.
  • 16
    Wekell P, Friman V, Balci-Peynircioglu B, Yilmaz E, Fasth A, Berg S. Familial mediterranean fever – an increasingly important childhood disease in Sweden. Acta Paediatr 2012;102:1938.
  • 17
    Ebrahimi-Fakhari D, Schonland S, Hegenbart U, Lohse P, Beimler J, Wahlster L et al. Familial Mediterranean fever in Germany: clinical presentation and amyloidosis risk. Scand J Rheumatol 2012;42:528.
  • 18
    Kim S, Ikusaka M, Mikasa G, Basugi A, Ohira Y, Nishizawa S et al. Clinical study of 7 cases of familial Mediterranean fever with MEFV gene mutation. Intern Med 2007;46:2215.
  • 19
    Tomiyama N, Higashiuesato Y, Oda T, Baba E, Harada M, Azuma M et al. MEFV mutation analysis of familial Mediterranean fever in Japan. Clin Exp Rheumatol 2008;26:137.
  • 20
    Arasawa S, Nakase H, Ozaki Y, Uza N, Matsuura M, Chiba T. Mediterranean mimicker. Lancet 2012;380:2052.
  • 21
    Lim AL, Jang HJ, Han JW, Song YK, Song WJ, Woo HJ et al. Familial Mediterranean fever: the first adult case in Korea. J Korean Med Sci 2012;27:14247.
  • 22
    Ben-Chetrit E, Touitou I. Familial Mediterranean fever in the world. Arthritis Rheum 2009;61:144753.
  • 23
    Alt HL, Barker MH. Fever of unknown origin. JAMA 1930;94:145761.
  • 24
    Siegal S. Benign paroxysmal peritonitis. Ann Intern Med 1945;23:121.
  • 25
    Siegal S. Benign paroxysmal peritonitis. Gastroenterology 1949;12:23447.
  • 26
    Eliakim M, Levy M, Ehrenfeld M. Recurrent polyserositis (familial Mediterranean fever). Amsterdam: Elsevier/North Holland Biomedical, 1981.
  • 27
    Reimann HA. Periodic disease; periodic fever, periodic abdominalgia, cyclic neutropenia, intermittent arthralgia, angioneurotic edema, anaphylactoid purpura and periodic paralysis. J Am Med Assoc 1949;141:17583.
  • 28
    Cattan R, Mamou H. 14 Cases of periodic disease, 8 of which are complicated by kidney diseases. Bull Mem Soc Med Hop Paris 1951;67:11047.
  • 29
    Mamou H, Cattan R. The periodic disease. Sem Hop 1952;28:106270.
  • 30
    Heller H, Sohar E, Sherf L. Familial Mediterranean fever. AMA Arch Intern Med 1958;102:5071.
  • 31
    Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med 1972;287:1302.
  • 32
    Gruberg L, Aksentijevich I, Pras E, Kastner DL, Pras M. Mapping of the familial Mediterranean fever gene to chromosome 16. Am J Reprod Immunol 1992;28:2412.
  • 33
    Pras E, Aksentijevich I, Gruberg L, Balow JE Jr, Prosen L, Dean M et al. Mapping of a gene causing familial Mediterranean fever to the short arm of chromosome 16. N Engl J Med 1992;326:150913.
  • 34
    French FMF. Consortium A candidate gene for familial Mediterranean fever. Nat Genet 1997;17:2531.
  • 35
    The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997;90:797807.
  • 36
    Babior BM, Matzner Y. The familial Mediterranean fever gene–cloned at last. N Engl J Med 1997;337:15489.
  • 37
    Holmes AH, Booth DR, Hawkins PN. Familial Mediterranean fever gene. N Engl J Med 1998;338:9923.
  • 38
    Berdeli A, Mir S, Nalbantoglu S, Kutukculer N, Sozeri B, Kabasakal Y et al. Comprehensive analysis of a large-scale screen for MEFV gene mutations: do they truly provide a “heterozygote advantage” in Turkey? Genet Test Mol Biomarkers 2011;15:47582.
  • 39
    Centola M, Wood G, Frucht DM, Galon J, Aringer M, Farrell C et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 2000;95:322331.
  • 40
    Tidow N, Chen X, Muller C, Kawano S, Gombart AF, Fischel-Ghodsian N et al. Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. Blood 2000;95:14515.
  • 41
    Stehlik C, Reed JC. The PYRIN connection: novel players in innate immunity and inflammation. J Exp Med 2004;200:5518.
  • 42
    Chae JJ, Komarow HD, Cheng J, Wood G, Raben N, Liu PP et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 2003;11:591604.
  • 43
    Chae JJ, Wood G, Masters SL, Richard K, Park G, Smith BJ et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA 2006;103:99827.
  • 44
    Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L et al. Gain-of-function Pyrin mutations induce NLRP3 protein-independent interleukin-1beta activation and severe autoinflammation in mice. Immunity 2011;34:75568.
  • 45
    Drenth JP, van der Meer JW. The inflammasome–a linebacker of innate defense. N Engl J Med 2006;355:7302.
  • 46
    Ting JP, Kastner DL, Hoffman HM. CATERPILLERs, pyrin and hereditary immunological disorders. Nat Rev Immunol 2006;6:18395.
  • 47
    Mimouni A, Magal N, Stoffman N, Shohat T, Minasian A, Krasnov M et al. Familial Mediterranean fever: effects of genotype and ethnicity on inflammatory attacks and amyloidosis. Pediatrics 2000;105:E70.
  • 48
    Akar N, Akar E, Yalcinkaya F. E148Q of the MEFV gene causes amyloidosis in familial Mediterranean fever patients. Pediatrics 2001;108:215.
  • 49
    Shohat M, Magal N, Shohat T, Chen X, Dagan T, Mimouni A et al. Phenotype-genotype correlation in familial Mediterranean fever: evidence for an association between Met694Val and amyloidosis. Eur J Hum Genet 1999;7:28792.
  • 50
    Livneh A, Langevitz P, Shinar Y, Zaks N, Kastner DL, Pras M et al. MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid 1999;6:16.
  • 51
    Shinar Y, Livneh A, Langevitz P, Zaks N, Aksentijevich I, Koziol DE et al. Genotype-phenotype assessment of common genotypes among patients with familial Mediterranean fever. J Rheumatol 2000;27:17037.
  • 52
    Kone PI, Dubuc M, Sportouch J, Minodier P, Garnier JM, Touitou I. Phenotype-genotype correlation in 91 patients with familial Mediterranean fever reveals a high frequency of cutaneomucous features. Rheumatology (Oxford) 2000;39:12759.
  • 53
    Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet 2001;9:47383.
  • 54
    Yildirim B, Tuncer C, Kan D, Tunc B, Demirag MD, Ferda PE et al. MEFV gene mutations and its impact on the clinical course in ulcerative colitis patients. Rheumatol Int 2011;31:85964.
  • 55
    Villani AC, Lemire M, Louis E, Silverberg MS, Collette C, Fortin G et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. PLoS ONE 2009;4:e7154.
  • 56
    Pras M. Amyloidosis of familial Mediterranean fever and the MEFV gene. Amyloid 2000;7:28993.
  • 57
    Touitou I, Picot MC, Domingo C, Notarnicola C, Cattan D, Demaille J et al. The MICA region determines the first modifier locus in familial Mediterranean fever. Arthritis Rheum 2001;44:1639.
  • 58
    Turkcapar N, Tuncali T, Kutlay S, Burhan BY, Kinikli G, Erturk S et al. The contribution of genotypes at the MICA gene triplet repeat polymorphisms and MEFV mutations to amyloidosis and course of the disease in the patients with familial Mediterranean fever. Rheumatol Int 2007;27:54551.
  • 59
    Cazeneuve C, Ajrapetyan H, Papin S, Roudot-Thoraval F, Genevieve D, Mndjoyan E et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet 2000;67:113643.
  • 60
    Bakkaloglu A, Duzova A, Ozen S, Balci B, Besbas N, Topaloglu R et al. Influence of Serum Amyloid A (SAA1) and SAA2 gene polymorphisms on renal amyloidosis, and on SAA/C-reactive protein values in patients with familial mediterranean fever in the Turkish population. J Rheumatol 2004;31:113942.
  • 61
    Lidar M, Yaqubov M, Zaks N, Ben-Horin S, Langevitz P, Livneh A. The prodrome: a prominent yet overlooked pre-attack manifestation of familial Mediterranean fever. J Rheumatol 2006;33:108992.
  • 62
    Kees S, Langevitz P, Zemer D, Padeh S, Pras M, Livneh A. Attacks of pericarditis as a manifestation of familial Mediterranean fever (FMF). Q J Med 1997;90:6437.
  • 63
    Majeed HA, Quabazard Z, Hijazi Z, Farwana S, Harshani F. The cutaneous manifestations in children with familial Mediterranean fever (recurrent hereditary polyserositis). A six-year study. Q J Med 1990;75:60716.
  • 64
    Eshel G, Vinograd I, Barr J, Zemer D. Acute scrotal pain complicating familial Mediterranean fever in children. Br J Surg 1994;81:8946.
  • 65
    Ozen S, Ben-Chetrit E, Bakkaloglu A, Gur H, Tinaztepe K, Calguneri M et al. Polyarteritis nodosa in patients with Familial Mediterranean Fever (FMF): a concomitant disease or a feature of FMF? Semin Arthritis Rheum 2001;30:2817.
  • 66
    Ertekin V, Selimoglu MA, Alp H, Yilmaz N. Familial Mediterranean fever protracted febrile myalgia in children: report of two cases. Rheumatol Int 2005;25:398400.
  • 67
    Gang N, Drenth JP, Langevitz P, Zemer D, Brezniak N, Pras M et al. Activation of the cytokine network in familial Mediterranean fever. J Rheumatol 1999;26:8907.
  • 68
    van der Hilst JC, Simon A, Drenth JP. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005;5:8798.
  • 69
    Livneh A, Langevitz P. Diagnostic and treatment concerns in familial Mediterranean fever. Baillieres Best Pract Res Clin Rheumatol 2000;14:47798.
  • 70
    Grateau G. The relation between familial Mediterranean fever and amyloidosis. Curr Opin Rheumatol 2000;12:614.
  • 71
    Obici L, Merlini G. Amyloidosis in autoinflammatory syndromes. Autoimmun Rev 2012;12:147.
  • 72
    Medlej-Hashim M, Delague V, Chouery E, Salem N, Rawashdeh M, Lefranc G et al. Amyloidosis in familial Mediterranean fever patients: correlation with MEFV genotype and SAA1 and MICA polymorphisms effects. BMC Med Genet 2004;5:4.
  • 73
    Sungur C, Sungur A, Ruacan S, Arik N, Yasavul U, Turgan C et al. Diagnostic value of bone marrow biopsy in patients with renal disease secondary to familial Mediterranean fever. Kidney Int 1993;44:8346.
  • 74
    Rozenbaum M, Naschitz JE, Yudashkin M, Rosner I, Sabo E, Shaviv N et al. Cardiovascular autonomic dysfunction in familial Mediterranean fever. J Rheumatol 2002;29:9879.
  • 75
    Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40:187985.
  • 76
    Yalcinkaya F, Ozen S, Ozcakar ZB, Aktay N, Cakar N, Duzova A et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford) 2009;48:3958.
  • 77
    Padeh S, Shinar Y, Pras E, Zemer D, Langevitz P, Pras M et al. Clinical and diagnostic value of genetic testing in 216 Israeli children with Familial Mediterranean fever. J Rheumatol 2003;30:18590.
  • 78
    Sarrauste de Menthiere C, Terriere S, Pugnere D, Ruiz M, Demaille J, Touitou I. INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 2003;31:2825.
  • 79
    Touitou I, Lesage S, McDermott M, Cuisset L, Hoffman H, Dode C et al. Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum Mutat 2004;24:1948.
  • 80
    Milhavet F, Cuisset L, Hoffman HM, Slim R, El-Shanti H, Aksentijevich I et al. The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat 2008;29:8038.
  • 81
    Infevers: an online database for autoinflammatory mutations. Copyright. (Available at http://fmf.igh.cnrs.fr/ISSAID/infevers/). Milhavet et al. Hum Mutat. 2008;29(6):803-8. Touitou et al. Hum Mutat. 2004 Sep;24(3):194-8; Sarrauste de Menthi‚re et al. Nucleic Acids Res. 2003 Jan 1;31(1):282-5. 2012.
  • 82
    Samuels J, Aksentijevich I, Torosyan Y, Centola M, Deng Z, Sood R et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore) 1998;77:26897.
  • 83
    Booty MG, Chae JJ, Masters SL, Remmers EF, Barham B, Le JM et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum 2009;60:185161.
  • 84
    Kogan A, Shinar Y, Lidar M, Revivo A, Langevitz P, Padeh S et al. Common MEFV mutations among Jewish ethnic groups in Israel: high frequency of carrier and phenotype III states and absence of a perceptible biological advantage for the carrier state. Am J Med Genet 2001;102:2726.
  • 85
    Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R et al. Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 2004;33:27382.
  • 86
    Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med 1974;291:9347.
  • 87
    Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E et al. A controlled trial of colchicine in preventing attacks of familial mediterranean fever. N Engl J Med 1974;291:9324.
  • 88
    Goldstein RC, Schwabe AD. Prophylactic colchicine therapy in familial Mediterranean fever. A controlled, double-blind study. Ann Intern Med 1974;81:7924.
  • 89
    Ben-Chetrit E, Levy M. Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum 1991;20:2416.
  • 90
    Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics 2007;119:e47483.
  • 91
    Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum 1994;37:180411.
  • 92
    Livneh A, Zemer D, Siegal B, Laor A, Sohar E, Pras M. Colchicine prevents kidney transplant amyloidosis in familial Mediterranean fever. Nephron 1992;60:41822.
  • 93
    Ben-Chetrit E, Ozdogan H. Non-response to colchicine in FMF–definition, causes and suggested solutions. Clin Exp Rheumatol 2008;26:S4951.
  • 94
    Onen F. Familial Mediterranean fever. Rheumatol Int 2006;26:48996.
  • 95
    Putterman C, Ben-Chetrit E, Caraco Y, Levy M. Colchicine intoxication: clinical pharmacology, risk factors, features, and management. Semin Arthritis Rheum 1991;21:14355.
  • 96
    Niel E, Scherrmann JM. Colchicine today. Joint Bone Spine 2006;73:6728.
  • 97
    Tufan A, Babaoglu MO, Akdogan A, Yasar U, Calguneri M, Kalyoncu U et al. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. J Rheumatol 2007;34:15404.
  • 98
    Lidar M, Kedem R, Langevitz P, Pras M, Livneh A. Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine. J Rheumatol 2003;30:26203.
  • 99
    Wright DG, Wolff SM, Fauci AS, Alling DW. Efficacy of intermittent colchicine therapy in familial Mediterranean fever. Ann Intern Med 1977;86:1625.
  • 100
    Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Ozaltin F et al. Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheumatol 2003;21:50914.
  • 101
    Belkhir R, Moulonguet-Doleris L, Hachulla E, Prinseau J, Baglin A, Hanslik T. Treatment of familial Mediterranean fever with anakinra. Ann Intern Med 2007;146:8256.
  • 102
    Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 2007;66:15456.
  • 103
    Gattringer R, Lagler H, Gattringer KB, Knapp S, Burgmann H, Winkler S et al. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky. Eur J Clin Invest 2007;37:9124.
  • 104
    Calligaris L, Marchetti F, Tommasini A, Ventura A. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur J Pediatr 2008;167:6956.
  • 105
    Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 2008;75:5045.
  • 106
    Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet's disease. Clin Rheumatol 2010;29:20910.
  • 107
    Alpay N, Sumnu A, Caliskan Y, Yazici H, Turkmen A, Gul A. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int 2012;32:32779.
  • 108
    Petropoulou AD, Robin M, Socie G, Galicier L. Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with anakinra. Transplantation 2010;90:1023.
  • 109
    Ozen S, Bilginer Y, Aktay AN, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol 2011;38:5168.
  • 110
    Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Kone-Paut I. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 2011;41:26571.
  • 111
    Stankovic SK, Delmas Y, Torres PU, Peltier J, Pelle G, Jeru I et al. Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant 2012;27:1898901.
  • 112
    Hashkes PJ, Spalding SJ, Giannini EH, Huang B, Johnson A, Park G et al. Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med 2012;157:53341.
  • 113
    Gafni J, Ravid M, Sohar E. The role of amyloidosis in familial mediterranean fever. A population study. Isr J Med Sci 1968;4:9959.
  • 114
    Brik R, Shinawi M, Kepten I, Berant M, Gershoni-Baruch R. Familial Mediterranean fever: clinical and genetic characterization in a mixed pediatric population of Jewish and Arab patients. Pediatrics 1999;103:e70.
  • 115
    Papin S, Duquesnoy P, Cazeneuve C, Pantel J, Coppey-Moisan M, Dargemont C et al. Alternative splicing at the MEFV locus involved in familial Mediterranean fever regulates translocation of the marenostrin/pyrin protein to the nucleus. Hum Mol Genet 2000;9:30019.
  • 116
    Matzner Y, Partridge RE, Levy M, Babior BM. Diminished activity of a chemotactic inhibitor in synovial fluids from patients with familial Mediterranean fever. Blood 1984;63:62933.
  • 117
    Matzner Y, Brzezinski A. C5a-inhibitor deficiency in peritoneal fluids from patients with familial Mediterranean fever. N Engl J Med 1984;311:28790.
  • 118
    Ayesh SK, Azar Y, Babior BM, Matzner Y. Inactivation of interleukin-8 by the C5a-inactivating protease from serosal fluid. Blood 1993;81:14247.
  • 119
    Ayesh SK, Azar Y, Barghouti II, Ruedi JM, Babior BM, Matzner Y. Purification and characterization of a C5a-inactivating enzyme from human peritoneal fluid. Blood 1995;85:35039.
  • 120
    Dale DC, Welte K. Cyclic and chronic neutropenia. Cancer Treat Res 2011;157:97108.
  • 121
    Gattorno M, Caorsi R, Meini A, Cattalini M, Federici S, Zulian F et al. Differentiating PFAPA syndrome from monogenic periodic fevers. Pediatrics 2009;124:e7218.
  • 122
    Posch C, Kaulfersch W, Rappersberger K. Cryopyrin-associated periodic syndrome. Pediatr Dermatol 2012. doi: 10.1111/j.1525-1470.2012.01812.x. [Epub ahead of print].
  • 123
    Sinha A, Waterham HR, Sreedhar KV, Jain V. Novel mutations causing hyperimmunoglobulin D and periodic fever syndrome. Indian Pediatr 2012;49:5835.
  • 124
    Stjernberg-Salmela S, Ranki A, Karenko L, Siitonen S, Mustonen H, Puolakkainen P et al. Low TNF-induced NF-kappaB and p38 phosphorylation levels in leucocytes in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 2010;49:38290.
  • 125
    Sfriso P, Caso F, Tognon S, Galozzi P, Gava A, Punzi L. Blau syndrome, clinical and genetic aspects. Autoimmun Rev 2012;12:4451.
  • 126
    Tanaka T, Takahashi K, Yamane M, Tomida S, Nakamura S, Oshima K et al. Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery. Blood 2012;120:1299308.
  • 127
    Goldbach-Mansky R. Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clin Exp Immunol 2012;167:391404.
  • 128
    Demidowich AP, Freeman AF, Kuhns DB, Aksentijevich I, Gallin JI, Turner ML et al. Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum 2012;64:20227.
  • 129
    Mendoza-Pinto C, Garcia-Carrasco M, Jimenez-Hernandez M, Jimenez HC, Riebeling-Navarro C, Nava ZA et al. Etiopathogenesis of Behcet's disease. Autoimmun Rev 2010;9:2415.
  • 130
    Grattagliano I, Bonfrate L, Ruggiero V, Scaccianoce G, Palasciano G, Portincasa P. Novel therapeutics for the treatment of familial mediterranean fever: from colchicine to biologics. Clin Pharmacol Ther 2013. doi: 10.1038/clpt.2013.148.